Earnings from current medicines
Novartis's higher profit outlook sits alongside a $1.9 billion impairment for del-desiran. Third-quarter sales rose 4% to $14.522 billion and core operating income rose 11% to $6.036 billion. Reported operating income fell 59% to $1.843 billion. For shareholders, the economic question is how to assess earnings from existing medicines alongside a loss on capital committed to a development-stage asset.[1]
Core results are useful for isolating the current business's earnings capacity. Sales volume supported growth, while generic competition and pricing reduced it. That bridge shows the 4% expansion came through a mechanism other than higher prices. The core operating margin of 41.6% measures improvement in operating earnings from medicines being sold. It does not answer what expectations justified committing capital to an asset in the past.[1]
The cost of development capital
The concrete basis for the impairment is the HARBOR trial: del-desiran did not meet its primary endpoint. Novartis is evaluating the complete data and plans to discuss the development path with health authorities. The partial impairment reduces the asset's carrying value, while the company has not announced that development has ended entirely. A capital allocation assessment therefore needs to recognise both the loss exposed by the trial and the development option that remains open.[1]
Dismissing core profit growth or dismissing the impairment would each leave the calculation incomplete. Earnings from current products and returns on capital allocated to the development portfolio answer different questions. Uncertainty in drug research does not make every unsuccessful project a mistaken investment from the outset. But excluding losses from core earnings does not remove shareholders' need to assess the cost of capital. This quarter requires operating performance and investment outcomes to be calculated separately and weighed together.[1]
Cash and expectations are separate calculations
Cash flow supplies a third measure. Free cash flow fell 18% to $5.111 billion, which the company attributed to lower net cash flows from operating activities. It moved in the opposite direction to core profit. An impairment does not itself mean a new cash payment of the same amount, so the cash decline cannot simply be attributed to the $1.9 billion expense. Cash conversion and asset revaluation affect shareholders through different channels.[1]
Management raised its annual constant-currency core operating income outlook from a low-single-digit decline to flat through low-single-digit growth. That improves the measure of current operations; it does not mean the capital committed to del-desiran has been recovered. The development decision and the economic benefit expected from the asset are central inputs to assessing capital allocation. An additional disclosed impairment in the development programme would be a concrete signal weakening the expected return on the remaining capital. The stronger core margin shows the current medicines business's earnings capacity, while the impairment keeps the cost of an earlier investment expectation in shareholders' accounts.[1]